Cerba Research, a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.
Cerba Research provides laboratory services for clinical trials to support areas such as medical testing, patient stratification and monitoring.
The company uses state-of-the-art technologies to support research and development (R&D) processes in areas such as oncology, immunology, genetics, microbiology and pathology.
Cerba Research has a global network of laboratories in the Americas, Europe, Africa and the Asia-Pacific (APAC) regions.
Pharmaceutical and biotech testing for clinical trials
Cerba Research offers customised testing services throughout clinical studies, from set-up to delivery. The company’s team of experts tests patient samples quickly and accurately, allowing pharmaceutical and biotechnology clients to focus on therapy development.
The company understands client requirements and is experienced with flow cytometry, histopathology, pharmacokinetics (PK) and biomarkers, as well as genetics and microbiology.
Project management and logistics for clinical studies
Cerba Research has more than 35 years of experience with handling complex logistical trials. The company organises procedures for studies in a wide range of therapeutic areas, including oncology, non-alcoholic steatohepatitis (NASH), infections, neurology and rare diseases.
The company’s project management services support open and pro-active communication between clinics while data is collected and recorded into a single global study database.
Cerba Research manufacturers kits that contain the materials required to obtain blood, urine, stool, cerebral spinal fluid (CSF) and bone marrow aspirate samples from patients. These kits follow Integrated Approaches to Testing and Assessment (IATA) regulations and include barcoded labels to facilitate sample tracking.
Custom assay development for precision medicine
Cerba Research recognises the importance of sharing scientific insights and implementing novel tests and customised assays.
The company helps develop precision medicine to provide the industry with customised solutions such as:
- Flexible solutions for complex flow cytometry needs
- Comprehensive cytokine profiling by selecting a panel of interest
- Immunoprofiling and biomarker analysis for patient inclusion and monitoring
- Molecular diagnostic tools
- High-level bioanalytical support in method development, validation and sample analysis of PK, pharmacodynamics (PD) and immunogenicity assays
- Technology transfers of assays
International network of routine medical laboratories
BARC is supported by the medical biological and diagnostic network Cerba Healthcare. Headquartered in Paris, Cerba HealthCare was founded in 1967. It comprises more than 450 routine medical labs, 150 sampling centres and additional facilities that specialise in clinical pathology, veterinary biology and genetics.
Cerba HealthCare has more than 6,300 collaborators to provide high-quality healthcare services to patients, physicians and biopharmaceutical companies. This network ensures that patients benefit from proximity, quality and innovative biology.
We reached an essential milestone in our company history in July, completing our US expansion. Leaning on our values of courage, innovation, and commitment, our increased capacity and expanded service offer enables us to continue growing our operational and scientific teams to support client needs.
Cerba Research today announced it was awarded a five-year contract for Clinical Central Laboratory Services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
Cerba Healthcare to Welcome EQT As New Shareholder to Foster Innovation and Continue to Meet the Healthcare Challenges
Cerba HealthCare, a leading player in medical diagnosis, together with Partners Group, and the Public Sector Pension Investment Board (PSP Investments), have entered exclusive discussions with EQT Private Equity to enable the Company to pursue its long-term innovation services strategy and enhance services for patients and the medical community.
The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola and other diseases called for the world to adjust and collaborate global research efforts.
Covid-19: Institut Imagine and Cerba HealthCare are Partnering to Test for Patients Likely to Develop Severe Symptoms
In 2020, researchers at Inserm, Université de Paris, and Assistance Publique–Hôpitaux de Paris (AP- HP), in collaboration with the university hospital organisation Institut Imagine (Hôpital Necker-Enfants malades AP-HP), which has been granted 'Institut Carnot' certification through the Rockefeller University and the Howard Hughes Medical Institute in New York, identified the leading genetic and immunological causes responsible for at least 15% of serious forms of Covid-19.
Cerba Research announces today that it has developed two new Covid-19 exploratory tools to enhance clinical research for the development of vaccines and treatments for Covid-19 and other infectious diseases.
BARC Lab and OWL Metabolomics are pleased to announce that they have entered a global strategic partnership combining BARC Lab’s industry-leading central lab services with Owl Metabolomics’ world-class metabolomics technology.